Traws Pharma, Inc. (TRAW)

Rigosertib Data Presented In Ultra-Rare Disease


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
October 13, 2023
Report ID: 26158
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Traws Pharma, Inc.
Traws Pharma, Inc.
Healthcare
Biotechnology
Ticker
TRAW
Current Price
$0.6957 1.9%
Market Cap
$14.6M
Price Target
Refer to Report
Volume
34.3K
52wk Range
$0.5509 - $1.45
Related Research Reports
4/3/2024

Transaction Forms A New Company In Virology and Oncology
Transaction Forms A New Company In Virology and Oncology (TRAW)
3/11/2024

Onconova To Present Data At American Association of Cancer Research Meeting
Onconova To Present Data At American Association of Cancer Research Meeting (TRAW)
12/13/2023

Poster Presentations Show Activity Of Narazaciclib In Breast Cancer and Lymphoma
Poster Presentations Show Activity Of Narazaciclib In Breast Cancer and Lymphoma (TRAW)
11/15/2023

3Q23 Reported With Several 2024 Milestones Announced
3Q23 Reported With Several 2024 Milestones Announced (TRAW)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.